XML 117 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2021
Apr. 30, 2021
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2023
Loss Contingencies [Line Items]          
Payments in equity, amount $ 10.0        
Lonza DMSA          
Loss Contingencies [Line Items]          
Percentage of defer payments agreed for completion   50.00%      
Amount recorded with respect to the potential future payments above the initial cash cap   $ 10.0      
Number of common stock issued 399,680        
Public offering price per share $ 25.02        
Sutro Biopharma Inc          
Loss Contingencies [Line Items]          
Number of common stock issued       167,780  
Upfront Consideration       $ 22.5  
Upfront Consideration in Cash       10.0  
Upfront Consideration in Cash After Agreement Date       5.0  
Option Exercise Price in Cash       75.0  
Additional Milestone Payments in Cash       60.0  
Accrued Commitment     $ 5.0 5.0  
Fair Value on Date of Settlement       8.0  
Sutro Biopharma Inc | Scenario Forecast          
Loss Contingencies [Line Items]          
Accrued payment         $ 5.0
Sutro Biopharma Inc | Common Stock          
Loss Contingencies [Line Items]          
Upfront Consideration       $ 7.5